筛状亚型多形性腺癌的综合分子特征:识别新融合及融合伴侣
研究识别出多种融合伴侣,包括13个新伴侣(3个复发),最常见为ARID1A和ARID1B。结果显示筛状亚型PAC融合伴侣高度多样,对疑难病例需更广泛的测序策略进行分子确认。
要点
- 筛状亚型PAC常伴PRKD1/2/3基因融合,NGS可识别多样融合伴侣。
- ARID1A和ARID1B是PRKD基因最常见的融合伴侣。
- 对FISH阴性或伴侣未知的疑难病例,建议采用NGS进行分子确认。
核心结论
- 筛状亚型PAC的PRKD基因融合伴侣高度多样,包括13个新伴侣,其中3个为复发伴侣。
- ARID1A和ARID1B是PRKD基因最常见的融合伴侣。
主要发现
- 28例检出PRKD1/2/3基因融合,10例检出PRKD1 p.E710D突变。
- 识别出多种融合伴侣,包括13个新伴侣,其中3个为复发伴侣。
- PRKD基因最常见的融合伴侣为ARID1A和ARID1B。
临床怎么用
- 对筛状亚型PAC,尤其FISH阴性或融合伴侣未知的疑难病例,可采用NGS进行分子确认。
- 检测PRKD1/2/3融合及PRKD1 p.E710D突变有助于分子分型。
局限性
- 研究仅纳入筛状及混合/中间型PAC以富集融合阳性病例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polymorphous adenocarcinoma (PAC) is a common, usually low-grade salivary gland carcinoma. While conventional PACs are most associated with PRKD1 p.E710D hotspot mutations, the cribriform subtype is often associated with gene fusions in PRKD1, PRKD2, or PRKD3. These fusions have been primarily identified by fluorescence in situ hybridization (FISH) analysis, with a minority evaluated by next-generation sequencing (NGS). Many of the reported fusions were detected by break-apart FISH probes and therefore have unknown partners or were negative by FISH altogether. In this study, we aimed to further characterize the fusions associated with PAC with NGS. Fifty-four PACs (exclusively cribriform and mixed/intermediate types to enrich the study for fusion-positive cases) were identified and subjected to NGS. Fifty-one cases were successfully sequenced, 28 of which demonstrated gene fusions involving PRKD1, PRKD2, or PRKD3. There were 10 cases with the PRKD1 p.E710D mutation. We identified a diverse group of fusion partners, including 13 novel partners, 3 of which were recurrent. The most common partners for the PRKD genes were ARID1A and ARID1B. The wide variety of involved genes is unlike in other salivary gland malignancies and warrants a broader strategy of sequencing for molecular confirmation for particularly challenging cases, as our NGS study shows.
引用
- Hahn E, Xu B, Katabi N, et al. Comprehensive Molecular Characterization of Polymorphous Adenocarcinoma, Cribriform Subtype: Identifying Novel Fusions and Fusion Partners. Mod Pathol. 2023. PMID: 37595638. doi:10.1016/j.modpat.2023.100305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。